TAVILERMIDE HYDROCHLORIDE

Possibly Marketed Outside US

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C24H32N6O11.ClH
Molecular Weight	617.005
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.NCCCC[C@@H]1NC(=O)[C@H](CCC(O)=O)NC(=O)C2=CC(=CC=C2OCC[C@H](NC1=O)C(=O)NCC(O)=O)[N+]([O-])=O

InChI

InChIKey=IHXKKAUOKMTRIF-FRKSIBALSA-N

InChI=1S/C24H32N6O11.ClH/c25-9-2-1-3-15-23(37)29-17(22(36)26-12-20(33)34)8-10-41-18-6-4-13(30(39)40)11-14(18)21(35)27-16(24(38)28-15)5-7-19(31)32;/h4,6,11,15-17H,1-3,5,7-10,12,25H2,(H,26,36)(H,27,35)(H,28,38)(H,29,37)(H,31,32)(H,33,34);1H/t15-,16-,17-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C24H32N6O11
Molecular Weight	580.5445
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23836957 | https://www.ncbi.nlm.nih.gov/pubmed/22349567 | https://clinicaltrials.gov/ct2/show/NCT01960010

Tavilermide (also known as MIM-D3) was developed as a tyrosine kinase TrkA receptor agonist for the treatment of patients with dry eye. The drug was studied in phase III clinical trial in treating the signs and symptoms of dry eye. In addition, was assumed that tavilermide could be studied for glaucoma.

Originator

Approval Year

PubMed

Title	Date	PubMed
Controlled Adverse Environment Chambers in Dry Eye Research.	2018-04	29336696
Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye.	2013	23836957
An NGF mimetic, MIM-D3, stimulates conjunctival cell glycoconjugate secretion and demonstrates therapeutic efficacy in a rat model of dry eye.	2011-10	21726552

Sample Use Guides

In Vivo Use Guide

A total of 150 dry eye patients were randomized 1:1:1 to study medication (1% MIM-D3 (TAVILERMIDE), 5% MIM-D3, or placebo) and dosed twice daily (BID) for 28 days.

Route of Administration: Other

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:31:30 GMT 2025` Edited by `admin` on `Mon Mar 31 21:31:30 GMT 2025`
Record UNII	7Q2C23X6YH
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TAVILERMIDE HYDROCHLORIDE

Official Name

English

MIM D-3 HYDROCHLORIDE

Preferred Name

English

3-(4R,7S,10S)-7-(4-AMINOBUTYL)-4-((CARBOXYMETHYL)AMINO)CARBONYL)-14-NITRO-6,9,12-TRIOXO-3,4,5,6,7,8,9,10,11,12-DECAHYDRO-2H-1,5,8,11-BENZOXATRIAZACYCLOTETRADECIN-10-YL) PROPANOIC ACID, HYDROCHLORIDE

Common Name

English

GLYCINE, N-(2-HYDROXY-5-NITROBENZOYL)-L-.ALPHA.-GLUTAMYL-L-LYSYL-L-HOMOSERYL-, CYCLIC (1->3)-ETHER HYDROCHLORIDE

Common Name

English

TAVILERMIDE HYDROCHLORIDE [USAN]

Common Name

English

D-3 HYDROCHLORIDE

Common Name

English

MPS-429

Code

English

MIM-D3 HYDROCHLORIDE

Code

English

Tavilermide hydrochloride [WHO-DD]

Common Name

English

Code System Code Type Description

NCI_THESAURUS

C167042